Kite Pharma (KITE) Tops Q4 EPS by 44c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/3/2026
- Wall Street rallies as Fed's Waller eases rate hike fears
- Fed’s Waller open to September rate hold - if disinflation holds up
- Broadcom raises AI chip forecast as Big Tech keeps writing bigger checks
- Nvidia to acquire AI platform Hugging Face in landmark $12.9B deal
- Tesla to unveil Cybercab Texas today, details are few
Kite Reports Fourth Quarter and Full Year 2016 Financial Results
February 28, 2017 8:00 AM ESTStrong Execution Across Clinical Development, Pipeline, Manufacturing and Pre-Commercial Activities in 2016 On Track to Complete Rolling Biologics License Application to the U.S. Food and Drug Administration for Axicabtagene Ciloleucel by End of First Quarter 2017 Potential U.S. Approval and Launch of Axicabtagene Ciloleucel Expected in 2017 Conference Call to Be Held Today at 9:00 AM Eastern Time
SANTA MONICA, Calif.--(BUSINESS WIRE)-- Kite Pharma, Inc. (Nasdaq: KITE) today provided a corporate update and reported fourth quarter and full-year 2016... More
